Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-100A with Bevacizumab and Carmustine for Recurrent GBM
NCT02348255Phase 2Withdrawn
- Sponsor
- University of California, Davis
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of California, Davis. Primary endpoints: Incidence of adverse events up to 12 months, Progression Free Survival at 6 months and 4 more. Planned start Jan 2016; status: withdrawn.
Beyond the preview
Go deeper on NCT02348255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348255.